Header Logo

Connection

Mary Rusckowski to Immunoconjugates

This is a "connection" page, showing publications Mary Rusckowski has written about Immunoconjugates.
Connection Strength

0.165
  1. Liu G, Dou S, Chen X, Chen L, Liu X, Rusckowski M, Hnatowich DJ. Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted. Cancer Biother Radiopharm. 2010 Dec; 25(6):757-62.
    View in: PubMed
    Score: 0.088
  2. Winnard P, Virzi E, Fogarasi M, Rusckowski M, Hnatowich DJ. Investigations of directly labeling antibodies with rhenium-188. Q J Nucl Med. 1996 Jun; 40(2):151-60.
    View in: PubMed
    Score: 0.032
  3. Hnatowich DJ, Virzi F, Fogarasi M, Rusckowski M, Winnard P. Can a cysteine challenge assay predict the in vivo behavior of 99mTc-labeled antibodies? Nucl Med Biol. 1994 Nov; 21(8):1035-44.
    View in: PubMed
    Score: 0.029
  4. Liu G, Dou S, Mardirossian G, He J, Zhang S, Liu X, Rusckowski M, Hnatowich DJ. Successful radiotherapy of tumor in pretargeted mice by 188Re-radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analogue. Clin Cancer Res. 2006 Aug 15; 12(16):4958-64.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.